10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELEVANCE HEALTH, INC. | |||
Ticker: ELV Fiscal Year: 2013 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2013 10-K (Filed: Feb 20, 2014) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | |
| Operating activities | |||
| Net income | $ 2,489,700 | 2,655,500 | 2,646,700 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Net realized gains on investments | (271,900) | (334,900) | (235,100) |
| Other-than-temporary impairment losses recognized in income | 98,900 | 37,800 | 93,300 |
| Loss on extinguishment of debt | 145,300 | 0 | 0 |
| Loss on disposal from discontinued operations | 221,800 | 0 | 0 |
| Loss on disposal of assets | 3,900 | 4,700 | 3,300 |
| Deferred income taxes | 59,100 | 127,500 | 74,300 |
| Amortization, net of accretion | 800,900 | 633,600 | 541,500 |
| Depreciation expense | 107,900 | 107,100 | 95,700 |
| Impairment of property and equipment | 47,700 | 66,800 | 0 |
| Share-based compensation | 146,000 | 146,500 | 134,800 |
| Excess tax benefits from share-based compensation | (30,100) | (28,800) | (42,200) |
| Changes in operating assets and liabilities, net of effect of business combinations: | |||
| Receivables, net | (418,300) | 189,900 | (401,800) |
| Other invested assets | (15,100) | (38,900) | (8,900) |
| Other assets | (33,600) | 79,200 | (259,200) |
| Policy liabilities | (345,800) | (53,700) | 978,000 |
| Unearned income | (73,800) | (193,700) | 35,100 |
| Accounts payable and accrued expenses | 303,600 | (406,500) | (208,700) |
| Other liabilities | (154,600) | (132,800) | (13,600) |
| Income taxes | 9,300 | (73,900) | (44,600) |
| Other, net | (38,600) | (40,800) | (14,200) |
| Net cash provided by operating activities | 3,052,300 | 2,744,600 | 3,374,400 |
| Investing activities | |||
| Purchases of fixed maturity securities | (13,704,500) | (15,040,400) | (11,914,800) |
| Proceeds from fixed maturity securities: | |||
| Sales | 10,977,900 | 13,675,900 | 10,446,200 |
| Maturities, calls and redemptions | 1,836,800 | 1,781,500 | 1,891,300 |
| Purchases of equity securities | (820,300) | (232,800) | (259,000) |
| Proceeds from sales of equity securities | 721,000 | 422,700 | 287,400 |
| Purchases of other invested assets | (251,500) | (303,700) | (207,900) |
| Proceeds from sales of other invested assets | 127,100 | 35,500 | 29,400 |
| Settlement of non-hedging derivatives | (109,800) | (59,800) | (96,600) |
| Changes in securities lending collateral | (405,100) | 307,900 | 28,900 |
| Purchases of subsidiaries, net of cash acquired | 0 | (4,597,000) | (600,000) |
| Purchases of property and equipment | (646,500) | (544,900) | (519,500) |
| Proceeds from sales of property and equipment | 39,200 | 400 | 3,700 |
| Other, net | 1,300 | 3,100 | (31,100) |
| Net cash used in investing activities | (2,234,400) | (4,551,600) | (942,000) |
| Financing activities | |||
| Net proceeds from (repayments of) commercial paper borrowings | (191,700) | (229,000) | 463,600 |
| Proceeds from long-term borrowings | 1,250,000 | 6,468,900 | 1,097,400 |
| Repayments of long-term borrowings | (1,801,900) | (1,251,300) | (705,100) |
| Proceeds from short-term borrowings | 1,100,000 | 642,000 | 100,000 |
| Repayments of short-term borrowings | (950,000) | (492,000) | (100,000) |
| Changes in securities lending payable | 405,000 | (307,800) | (29,000) |
| Changes in bank overdrafts | 9,900 | (17,600) | 264,300 |
| Premiums paid on equity options | (25,800) | 0 | 0 |
| Repurchase and retirement of common stock | (1,620,100) | (2,496,800) | (3,039,800) |
| Cash dividends | (448,000) | (367,100) | (357,800) |
| Proceeds from issuance of common stock under employee stock plans | 524,700 | 110,800 | 245,000 |
| Excess tax benefits from share-based compensation | 30,100 | 28,800 | 42,200 |
| Net cash (used in) provided by financing activities | (1,717,800) | 2,088,900 | (2,019,200) |
| Effect of foreign exchange rates on cash and cash equivalents | 2,200 | 1,100 | (400) |
| Change in cash and cash equivalents | (897,700) | 283,000 | 412,800 |
| Cash and cash equivalents at beginning of year | 2,484,600 | 2,201,600 | |
| Cash and cash equivalents at end of year | 1,586,900 | 2,484,600 | 2,201,600 |
| Less cash and cash equivalents of discontinued operations at end of year | (4,800) | (9,300) | 0 |
| Cash and cash equivalents of continuing operations at end of year | 1,582,100 | 2,475,300 | 2,201,600 |
| External Links | |
| ELEVANCE HEALTH, INC. (ELV) Fiscal Year 2013 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |